57 results about "Poly l arginine" patented technology

The invention provides an ER targeting self-assembly AIE probe with cascade ROS / RNS generation performance, and belongs to the technical field of material chemistry, the probe is composed of four units: 1) an AIE photosensitizer OTBS used for generating ROS; 2) deriving peptide FFVLK from beta amyloid protein, and promoting the self-assembly of the peptide to form a nanofiber with a beta-sheet structure; (3) an oligomerization arginine unit RRRR which is used as an NO donor; and 4) ER targeting signal peptide KDEL to endow ER with targeting ability. Based on ER targeting and a self-assembly process, the self-assembly AIE probe is subjected to ER in-situ self-assembly in cells to form nanofibers, ROS / RNS is generated in a cascading manner under illumination, and strong ICD is induced. In addition, the tumor residence time of the photosensitizer is prolonged due to the formation of the nanofibers, and the treatment effect is further improved. The invention provides a new thought for the design of a novel light-operated II-type ICD inducer.

The invention discloses a sodium iodide probe assisted gold nanoparticle-polyarginine-polylysine electrochemical sensor and an application thereof. The composite electrode provided by the invention comprises an electrode substrate and a nano composite film modified on the surface of the electrode substrate, the nano composite membrane comprises gold nanoparticles, polyarginine and polylysine. The invention further provides an electrochemical sensor which is constructed by combining the sodium iodide probe and the composite electrode and is used for detecting nitrite. The electrochemical sensor has the advantages of simplicity, rapidness, low detection limit, wide response range, good reproducibility, high selectivity and the like. The electrochemical sensor can be used for measuring the content of nitrite in beef and tap water samples, the recovery rate is satisfactory, and the electrochemical sensor has potential application prospects in the aspects of food safety and environmental protection.

The present disclosure provides for polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a polyarginine peptide and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the polyarginine peptide. The present disclosure demonstrates that cCPPs conjugated to polyarginine peptides can be used to deliver nucleic acids to the cytosol of cells.

The invention discloses a polyarginine nano-particle as well as a preparation method and application thereof. The preparation method comprises the following steps: polymerizing ornithine-carboxylic anhydride (NCA) serving as a monomer with leucine to obtain a diblock polymer, or polymerizing the ornithine-carboxylic anhydride monomer, and then performing guanidination treatment and self-assembly to obtain the polyarginine nanoparticles. The polyarginine nano-particles prepared by the invention can be combined with free nucleic acid released by injured tissues or cells in traumatic brain injury (TBI) to remove the free nucleic acid and prevent downstream immune response reaction, so that the proinflammatory factor level is remarkably reduced, and the purposes of relieving inflammation and treating TBI are achieved; compared with the traditional cationic amino acid (polylysine), the polyarginine material adopted by the invention can effectively improve the prognosis of TBI patients. Therefore, the invention provides the nano material with remarkably improved DNA binding capacity and treatment effect, and the nano material has important significance in treatment of traumatic brain injury.

The invention provides an antibacterial agent based on co-assembly of an anionic surfactant and polyarginine, and particularly relates to a safe and efficient antibacterial agent. The antibacterial agent provided by the invention is an aggregate formed by co-assembly of polyarginine (Arg) n and an anionic surfactant, and the preparation method is simple. The antibacterial agent is high in safety and has no toxicity to mammalian cells; the compound has remarkable antibacterial activity on escherichia coli and staphylococcus aureus. According to the invention, the assembly structure of the antibacterial agent can be regulated and controlled by adjusting the number (such as 4, 8, 12 or 16) of arginine in the polyarginine and the charge ratio between the polyarginine and the anionic surfactant; and when the layered structure is formed, the antibacterial agent has the strongest antibacterial activity. Meanwhile, in a mouse in-vivo experiment, the antibacterial agent also shows efficient antibacterial activity and can promote wound healing.

Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and / or transport therapeutic drugs across the blood brain barrier.

The application discloses a kind of R8 and Tf co-modified mebendazole liposome targeted preparation and its preparation method, application, belong to the field of biological medicine. In view of the poor solubility of mebendazole in water, difficult to penetrate blood-brain barrier, the problem of insufficient tumor targeting in brain glioma treatment, the application adopts film hydration-step modification process, and octaarginine (R8) and targeting ligand transferrin (Tf) are simultaneously modified on the surface of mebendazole-loaded liposome, and the preparation prepared by the application has an encapsulation efficiency of not less than 95%. The preparation can break through blood-brain barrier and precisely enrich in brain glioma lesions, and the in-vivo tumor inhibition rate is more than 90%, with low toxicity and side effects. The preparation can be used for preparing brain glioma therapeutic drugs, and provides a new drug for targeted treatment of brain glioma.

The invention provides a short polyarginine modified DNA probe as well as a preparation method and application thereof, and belongs to the technical field of biological analysis and detection. The preparation method of the short polyarginine modified DNA probe comprises the following steps: dissolving base-deficient site DNA in a buffer solution, and adding a coupling molecule linker for reaction to obtain an intermediate; and adding the purified intermediate into an Arg5-PEG1000-azide solution, and carrying out a click chemical reaction, so as to obtain the short polyarginine modified DNA probe. The invention also provides the short polyarginine modified DNA probe and application thereof. The short polyarginine modified DNA probe can generate characteristic and recognizable current signals through the nanopores so as to realize enzyme and small molecule detection, and has the advantages of high signal frequency, strong specificity, simple synthesis and great application potential.

The invention discloses a macrophage immune activation method based on aggregate mediated magnesium ion delivery. The method comprises the following steps: in a buffer environment containing magnesium ions, preparing a biomolecular aggregate formed by compounding polyarginine and polyadenylic acid through liquid-liquid phase separation, and enriching the magnesium ions by the aggregate through multivalent chelation; diluting the aggregate loaded with high-concentration magnesium ions in a cell culture medium to obtain a biomolecular aggregate suspension; and sequentially adding the target cell suspension and the biomolecular aggregate suspension into a cell culture dish, fully mixing, and then transferring the cell culture dish into a carbon dioxide cell incubator for standing culture. According to the method, the biomolecular aggregate loaded with the high-concentration magnesium ions is co-cultured with the cells, and the high-concentration magnesium ions are delivered into the cells in a short time, so that the immune level of the cells is improved, and the activity and safety of the cells are ensured.

The present invention discloses a long-acting antioxidant intelligent targeted nano antifouling agent and a preparation method thereof, belonging to the field of marine biofouling protection. Through electrostatic interaction, a fouling-sensitive responsive polymer is self-assembled onto the surface of an inorganic nano-functional core. The fouling-sensitive responsive polymer is sodium polyacrylate and polyarginine, and the surface of the inorganic nano-functional core is metal oxide nanoparticles. Sodium polyacrylate and polyarginine are alternately self-assembled on the surface of the metal oxide nanoparticles. Each time sodium polyacrylate and polyamino acid are alternately self-assembled, a layer of fouling-sensitive responsive polymer is coated on the inorganic nano-functional core until a complete fouling-sensitive polymer shell is formed on the surface of the inorganic nano-functional core. The preparation process of the present invention is simple, fast, safe and non-toxic, meeting the development requirements of environmental friendliness; for biological fouling, the nano antifouling agent of the present invention has intelligent targeted release, with short-term recognition and long-acting bactericidal functions.

The present invention discloses a sensitizing film for radioactive stents and a preparation method thereof, aiming to overcome the existing radiotherapy stents' great damage to normal tissues and the shortcomings of traditional sensitizing drug coating materials. The sensitizing film for radioactive stents includes a first film layer and a second film layer, wherein the first film layer is a polyurethane support layer, and the second film layer contains a radiosensitizing drug component; the platinum radiosensitizing drug is oxidized to a tetravalent platinum drug, a polyarginine targeting group is introduced for modification, and then PLGA50:50 with a molecular weight of 5k is used for modification; the first film layer composed of polyurethane and the second film layer composed of PLGA75:25 with a molecular weight of 100k and containing a radiosensitizing drug component are prepared by electrospinning technology. The sensitizing film for radioactive stents of the present invention has the advantages of high targeting, low toxicity and side effects, high efficiency sensitization, good support, sustained release, and simple and efficient preparation process, providing a new, safe and effective treatment method for the field of intracavitary tumor radiotherapy.

The present invention relates to a process for preparation of linear polylysine or polyarginine by chemoenzymatic bulk polymerization of lysine ester or arginine ester respectively. The present invention also relates to a method for controlling regioselectivity of polylysine or polyarginine in the chemoenzymatic bulk polymerization of lysine ester or arginine ester.

The invention relates to a wound dressing (2) for wound treatment in a moist or moist / wet environment, having a fibrous nonwoven-based absorbing / rinsing body (4) in which superabsorbent material is received in a distributed manner, wherein a saline aqueous solution, in particular Ringer's solution, is applied to the absorbing / rinsing body (4) by the manufacturer, and having a cover (6) forming the outer visible sides of the wound dressing, wherein the cover (6) comprises, on the wound-facing side of the wound dressing, a textile surface material (9), in particular composed of a weft-knitted fabric, warp-knitted fabric or woven fabric, wherein the cover (6) has, on the wound-facing side of the wound dressing, an antimicrobial coating (22) which has been applied to part or all of the outer side and which comprises a hyaluronic acid and a polypeptide chosen from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides.

The application discloses an activatable cell-penetrating peptide, a preparation method, a drug delivery method and an application thereof. The activatable cell-penetrating peptide comprises polypeptide segment 1 and polypeptide segment 2; the polypeptide segment 1 comprises a peptide chain 1, the N terminal of the peptide chain 1 is acetylated and connected with a cyclic peptide RGD, and a group with a cyano group is further connected to the peptide chain 1; the polypeptide segment 2 comprises a peptide chain 2, the N terminal of the peptide chain 2 is also connected with a cyclic peptide RGD, and the peptide chain 2 contains cysteine. The application designs a novel strategy of in-situ activatable cell-penetrating peptide based on an activation nitrile-amino thiol coupling reaction, and the cell-penetrating peptide is composed of two independent low cell-penetrating activity polyarginine polypeptides; after reaching a target site, the two are coupled in-situ through the above-mentioned click chemistry reaction to generate an octa-arginine sequence with high cell-penetrating ability. The design of the 'on-demand activation' not only restores the cell-penetrating function, but also significantly reduces the cytotoxicity caused by non-specific penetration.

The invention relates to a silicone-containing, antimicrobial wound contact layer having, on the wound side, a partial or complete antimicrobial coating comprising i) a hyaluronic acid and ii) a polypeptide selected from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides. The invention also relates to absorbent wound dressings containing said wound contact layer, and to methods for producing the wound contact layer.

The application belongs to the field of fertilizers, and particularly relates to a high-nitrogen-fertilizer utilization rate foliar fertilizer and a preparation method thereof. Glycidyl methacrylate is used to prepare a polymer, and then polyarginine is used to modify the polymer to obtain a composite matrix. Part of the composite matrix is combined with 3,4,9,10-perylenetetracarboxylic dianhydride to obtain a photosensitive matrix. The photosensitive matrix is used as a ligand, metal ions are combined with the ligand to form a complex, and the complex is compounded with the composite matrix and soluble compounds of nutrient elements to obtain the foliar fertilizer. The high-nitrogen-fertilizer utilization rate foliar fertilizer can promote photosynthesis of plants, promote root growth, and improve nitrogen absorption and utilization of plants.

The invention discloses a DNase I-loaded pilose antler stem cell exosome and a preparation method and application thereof, and belongs to the technical field of biological medicine, DNase I enzyme is stably and efficiently loaded on the surface of the pilose antler MSCs exosome through electrostatic adsorption of poly-arginine polypeptide, and the DNase I-loaded pilose antler stem cell exosome is prepared by combining the immune regulation function and the arthritis focus targeting characteristic of the exosome. And multi-mechanism accurate treatment on inflammatory diseases such as rheumatoid arthritis is realized. According to the technology, the drug loading efficiency and the structural stability of the exosome are remarkably improved, the biological activity and the anti-inflammatory effect of the DNase I are effectively reserved, the application obstacles that a traditional protein drug is unstable in vivo, easy to remove, poor in targeting property and the like are overcome, and good treatment prospects and conversion values are achieved. Therefore, the invention has remarkable innovativeness and practicability, is suitable for functional modification of exosome drugs and treatment of various chronic inflammation related diseases, and has important industrialization and clinical popularization prospects.

The invention discloses a degradable magnesium alloy intravascular stent based on bionic hydrogel and nitric oxide double-path release and a preparation method and application thereof. The method comprises the steps that a magnesium alloy base material is subjected to alkali heat treatment; immersing the treated magnesium alloy into a silane coupling agent for reaction; the photopolymerization reaction liquid is treated to the surface of the silanization modified magnesium alloy, and polymerization is conducted through ultraviolet irradiation; immersing the magnesium alloy with the hydrogel coating into a polyarginine solution, and grafting polyarginine onto the surface of the hydrogel; a sample is activated through EDC / NHS and then immersed in a selenocystamine solution for a reaction, and the bionic composite coating, with the exogenous / endogenous dual-path nitric oxide release function, of the degradable magnesium alloy intravascular stent is obtained. The invention successfully constructs the bionic coating integrating cell membrane-imitating anti-fouling and exogenous / endogenous dual-path NO release functions, and the coating effectively solves the key problems of corrosion control, thrombus formation resistance, functional re-endothelialization coordinated regulation and the like faced by the degradable magnesium alloy intravascular stent.

The invention relates to a polyarginine-DNA nanotube material as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Aiming at the technical problems of unstable structure, low cell uptake rate and easy degradation by nuclease caused by dependence on magnesium ions in the existing DNA nano-material, the invention provides a nano-tube material formed by self-assembly of four DNA single chains (Y1-Y4) according to a molar ratio of 1: 3: 3: 3 induced by polyarginine. The material can load p65 siRNA to form a composite preparation which is used for preparing a medicine for inhibiting lung inflammation. According to the polyarginine-DNA nanotube material disclosed by the invention, the stability and the cell uptake efficiency of the material are remarkably improved; the higher the polymerization degree of arginine is, the stronger the anti-inflammatory activity is; the compound preparation synergistically inhibits the expression of a proinflammatory factor through a dual mechanism of blocking an inflammatory pathway by polyarginine and silencing a p65 signal by p65 siRNA, and provides an efficient delivery carrier for the treatment of acute lung injury.

The invention belongs to the technical field of biological medicine, and particularly discloses fluorouracil sustained-release nano-microspheres as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, dissolving fluorouracil in a polyarginine aqueous solution, uniformly stirring, and adjusting the pH value to 7.2-7.4 to obtain a fluorouracil solution; s2, dissolving amphiphilic alginate in water, sequentially adding carboxymethyl chitosan and quaternized gelatin, and uniformly stirring to obtain a composite carrier solution; and S3, mixing the fluorouracil solution obtained in the step S1 with the composite carrier solution obtained in the step S2, performing ultrasonic treatment, performing self-assembly, performing centrifugation, and collecting precipitates to obtain the fluorouracil nano-microspheres. The invention discloses a fluorouracil sustained-release nano-microsphere as well as a preparation method and application thereof. The fluorouracil sustained-release nano-microsphere can be used for remarkably improving the encapsulation efficiency and the drug loading capacity of fluorouracil, realizing long-acting sustained release of drugs, enhancing the tumor targeting property and the cell uptake efficiency and improving the treatment effect.

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

A recombinant TEV protease, a preparation method therefor, and use thereof, relating to the technical field of biology. Specifically provided are four recombinant TEV proteases derived from a cysteine protease of tobacco etch virus. In each of the four recombinant TEV proteases, the N-terminus is fused with an 8His-CL7-GGS tag, and the C-terminus is fused with a polyarginine tag. Compared to a wild-type TEV protease, the provided four recombinant TEV proteases not only can overcome defects such as self-cleavage, poor solubility, and low activity during expression and purification of the wild-type TEV protease, but also have improved protein yield 5-6 times higher than that of the wild-type TEV enzyme, and enzyme activity 10-20 times higher than that of the wild-type TEV protease. In addition, the engineered TEV protease mutants also possess higher thermal stability with a Tm value 10-30 °C higher than that of the wild-type TEV protease, exhibit better protein stability, have broader application conditions, and are more suitable for large-scale production and industrial use.

The invention relates to a C-DC dendritic cell albumin suspension capable of specifically eliminating high-risk HPV virus infection in a targeting manner and a preparation method thereof, and belongs to the field of medicines, and the preparation method comprises the following steps: synthesizing a multi-valence HPV dominant antigen epitope peptide which is synthesized by connecting carboxyl groups at C-terminals of four HPV epitope peptides with amino groups of a poly-arginine skeleton formed by three arginine residues; then preparing a C-DC dendritic cell albumin suspension by using the multi-valence HPV dominant antigen epitope peptide; and pre-cancerous and cancerous cells infected and caused by various high-risk HPV viruses are eliminated by using a C-DC immunotherapy. By synthesizing the multi-valence HPV dominant antigen epitope peptide and combining with C-DC immunotherapy, a treatment method with higher pertinence and effectiveness is developed, a new effective treatment choice is provided for high-risk HPV infection and canceration patients, and the multi-valence HPV dominant antigen epitope peptide has wide market prospects, can provide personalized treatment schemes for the patients and can improve the treatment effect and safety.

The invention discloses a ternary co-modified engineered cornu cervi pantotrichum MSCs exosome and a preparation method and application thereof, and belongs to the technical field of biological medicine, the ternary co-modified engineered cornu cervi pantotrichum MSCs exosome comprises a cornu cervi pantotrichum MSCs exosome, a poly-arginine polypeptide-deoxyribonuclease I compound located on the surface of the cornu cervi pantotrichum MSCs exosome, and an RGD polypeptide modified on the surface of the cornu cervi pantotrichum MSCs exosome and containing an Arg-Gly-Asp sequence. In order to solve the problem that an integrated treatment mode of multiple pathological links cannot be realized during existing RA treatment, three active components, namely poly-arginine polypeptide (P-Arg), deoxyribonuclease I (Dnase I) and RGD polypeptide, are cooperatively modified on the surface of an exosome of pilose antler MSCs for the first time to form a surface engineering modified exosome complex; multiple functions of immunoregulation, cfDNA removal, targeted delivery and tissue protection can be realized in RA focuses, and a brand-new and systematic treatment means is provided for rheumatoid arthritis.

The present invention relates to a process for preparation of linear polylysine or polyarginine by chemoenzymatic bulk polymerization of lysine ester or arginine ester respectively. The present invention also relates to a method for controlling regioselectivity of polylysine or polyarginine in the chemoenzymatic bulk polymerization of lysine ester or arginine ester.

The invention discloses a sensitization film for a radioactive stent and a preparation method of the sensitization film, and aims to overcome the defects that an existing radiotherapy stent causes great damage to normal tissues and a traditional sensitization drug coating material is insufficient. The sensitization film for the radioactive stent comprises a first film layer and a second film layer, the first film layer is a polyurethane supporting layer, and the second film layer contains radiosensitization medicine components; the preparation method comprises the following steps: oxidizing a platinum radiosensitization drug into a tetravalent platinum drug, introducing a polyarginine targeting group for modification, and then modifying by using PLGA 50: 50 with the molecular weight of 5k; a first film layer composed of polyurethane and a second film layer which is composed of PLGA 75: 25 with the molecular weight of 100 k and contains radiosensitization medicine components are prepared through the electrostatic spinning technology. The sensibilization film for the radioactive stent has the advantages of high targeting property, low toxic and side effects, high sensibilization efficiency, good supporting property, continuous slow release, simple and efficient preparation process and the like, and a novel, safe and effective treatment means is provided for the field of radiotherapy of tumors in a cavity.

The invention relates to a wound covering comprising at least one plastic mesh and one absorbent non-woven material, wherein at least the mesh has an antimicrobial coating. The coating comprises a hyaluronic acid and a polypeptide selected from polyarginine, polylysine and polyornithine or a mixture of at least two of the aforementioned polypeptides. The invention also relates to methods for applying the coating, and to wound coverings comprising the antimicrobial non-woven fabric. The coating is distinguished by its good compatibility and cell compatibility as well as its strong antiseptic action.

The present invention provides a polyarginine modified peptide derived from the traditional Chinese medicine American cockroach and its application. The nucleotide sequence of the polyarginine modified peptide derived from the traditional Chinese medicine American cockroach is shown in SEQ ID NO.1. The modified peptide can be prepared by using a polypeptide solid phase synthesis technology, and has the characteristics and advantages of mature preparation technology, high yield, good purity, strong stability, etc. At the same time, it has a wide antibacterial spectrum and has good antibacterial (including Gram-positive cocci and Gram-negative bacilli) and antifungal (Candida fungi) activities. MTT experiments and hemolytic activity studies show that it also has low cytotoxicity and has good application prospects and development value.

The present invention relates to a method for preparing linear polylysine or polyarginine by chemoenzymatic bulk polymerization of lysine esters or arginine esters, respectively. The invention also relates to a method for controlling the regioselectivity of polylysine or polyarginine in the chemoenzymatic bulk polymerization of lysine esters or arginine esters.

Particles are provided that include (a) a liposome having a negatively charged outer surface; (b) a first layer comprising poly-L-arginine (PLR), wherein the PLR is non-covalently associated with the negatively charged outer surface of the liposome; (c) a second layer, comprising hyaluronate (HA), wherein the HA is non-covalently associated with the first layer; and (d) a blood brain barrier-targeting peptide layer electrostatically coupled to the second layer; as are particles that are loaded with a therapeutic and their use for treating a brain cancer.